Schrödinger, Inc.

SDGR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $230.5M $147.3M $155.3M $90.5M $120.3M $202.3M $26.0M
Accounts Receivable $83.0M $235.7M $66.0M $56.0M $31.7M $31.4M $18.7M
Inventory — — — — — — —
Total Current Assets $519.3M $635.0M $567.8M $534.0M $625.1M $683.0M $118.5M
Property, Plant & Equipment — — — $14.2M $10.0M $5.1M $6.3M
Goodwill $4.8M $4.8M $4.8M $4.8M $0 — —
Intangible Assets (Excl. Goodwill) — — $0 $587.0K $0 — —
Total Assets $726.2M $823.2M $803.0M $688.6M $756.5M $746.3M $155.3M
Liabilities
Accounts Payable $11.5M $10.7M $16.8M $9.5M $8.1M $8.4M $3.5M
Total Current Liabilities $189.1M $191.7M $133.7M $108.8M $91.2M $73.2M $45.0M
Long-Term Debt — — — — — — —
Total Liabilities $362.1M $401.8M $254.4M $240.7M $199.4M $122.2M $57.0M
Stockholders' Equity
Retained Earnings $-628.8M $-525.5M $-338.4M $-379.1M $-230.0M $-129.6M $-105.1M
Total Stockholders' Equity $364.1M $421.4M $548.6M $447.9M $557.1M $624.0M $-93.4M